๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Therapy of mouse mammary carcinomas with vincristine and doxorubicin encapsulated in sterically stabilized liposomes

โœ Scribed by Jan Vaage; Dorothy Donovan; Eric Mayhew; Paul Uster; Martin Woodle


Publisher
John Wiley and Sons
Year
1993
Tongue
French
Weight
431 KB
Volume
54
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


Therapy of primary and metastatic mouse
โœ Jan Vaage; Eric Mayhew; Dan Lasic; Frank Martin ๐Ÿ“‚ Article ๐Ÿ“… 1992 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 639 KB

The purpose of our study was to compare the therapeutic effects of doxorubicin in 3 different formulations: (I) in PBS, (2) in conventional liposomes composed of egg phosphatidylglycerol/ egg phosphatidylcholine/cholesterol/dl-a tocopherol, and (3) in sterically stabilized, long-circulating "Stealth

Therapy of human ovarian carcinoma xenog
โœ Jan Vaage; Dorothy Donovan; Eric Mayhew; Robert Abra; Anthony Huang ๐Ÿ“‚ Article ๐Ÿ“… 1993 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 410 KB

Background. This study compared the therapeutic effects of doxorubicin hydrochloride in saline and in sterically stabilized, long-circulating liposomes composed of hydrogenated soy phosphatidylcholine/cholesteroljpolyethylene glycol-distearoyl-phosphatidyl-ethanolamine (Doxil]. Methods. The drug fo

Pharmacokinetics and anti-tumor activity
โœ Theresa M. Allen; Mary S. Newman; Martin C. Woodle; Eric Mayhew; Paul S. Uster ๐Ÿ“‚ Article ๐Ÿ“… 1995 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 767 KB

Vincristine is used clinically for the treatment of various types of cancer. Recent significant therapeutic improvements obtained by entrapping anthracyclines in sterically stabilized liposomes raised the question whether the therapeutic index of vincristine can be similarly increased by formulation

Inhibition of mouse mammary carcinoma de
โœ Jan Vaage; Peter Working; Paul Uster ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 35 KB

Monthly treatments with intravenous doxorubicin encapsulated in long circulating, sterically stabilized liposomes delayed the appearance of primary mammary carcinomas and reduced the final incidence from 49 in 50 untreated mice to 46 in 87 treated mice. No toxic side effects of the treatments were o